Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for (…)
Site référencé:
The Guardian
5600.jpg?width=140&quality=85&auto=format&fit=max&s=3c9fbe44095ac082c7d3ab69690c3997, 5600.jpg?width=460&quality=85&auto=format&fit=max&s=cfb59dc39e88893fa40a3c4f100554b7, 5600.jpg?width=700&quality=85&auto=format&fit=max&s=a68123dfb611648b76cc65a9b7551f47
The Guardian
Lily Allen announces UK theatre tour for her West End Girl album
30/10/2025
England’s Michelle Agyemang faces long injury absence after rupturing ACL
30/10/2025
UK rule change allows some Palestinian scholars to bring families from Gaza
30/10/2025
Is it OK to talk at the cinema ? How about if it’s just during the trailers ? | Polly Hudson
30/10/2025
Slang terms like ‘six-seven’ have no definition. But they’re loaded with meaning | Matthew Cantor
30/10/2025
Thursday news quiz : Dachshunds, Dave Ball, drag acts and data disasters
30/10/2025